Welcome to the Integrated Research Application System

IRAS Project Filter

The integrated dataset required for your project will be created from the answers you give to the following questions. The system will generate only those questions and sections which (a) apply to your study type and (b) are required by the bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications.

Please complete the questions in order. If you change the response to a question, please select ‘Save’ and review all the questions as your change may have affected subsequent questions.

Please enter a short title for this project (maximum 70 characters)
Toxicity from Anti-TNF Therapy

REC details:

Name of main REC:
North West 5 Research Ethics Committee

REC Reference Number:
00/8/53

NRES form lock code:

1. Select one category from the list below:
   - Clinical trial of an investigational medicinal product
   - Study only involving data or tissues not identifiable to the researcher

   If your work does not fit any of these categories, select the option below:
   - Other study

2. Does the study involve the use of any ionising radiation?
   - Yes
   - No

3. In which countries of the UK will the research sites be located? (Tick all that apply)
   - England
   - Scotland
   - Wales
   - Northern Ireland

3a. In which country of the UK will the lead NHS R&D office be located:
   - England
   - Scotland
   - Wales
   - Northern Ireland
   - This study does not involve the NHS
4. Do you plan to include any participants who are children?

- [ ] Yes
- [x] No

5. Do you plan to include any participants who are adults unable to consent for themselves through physical or mental incapacity?

- [ ] Yes
- [ ] No

*Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the study following loss of capacity. Intrusive research means any research with the living requiring consent in law. This includes use of identifiable tissue samples or personal information, except where application is being made to the Confidentiality Advisory Group to set aside the common law duty of confidentiality in England and Wales. Please consult the guidance notes for further information on the legal frameworks for research involving adults lacking capacity in the UK.*

6. Is the study or any part of it being undertaken as an educational project?

- [ ] Yes
- [ ] No
NOTICE OF SUBSTANTIAL AMENDMENT
Please use this form to notify the main REC of substantial amendments to all research other than clinical trials of investigational medicinal products (CTIMPs).
The form should be completed by the Chief Investigator using language comprehensible to a lay person.

Details of Chief Investigator:

Title Forename/Initials Surname
Prof Deborah Symmons

Work Address Arthritis Research UK Epidemiology
Unit, 2nd Floor Stopford Bldg,
Oxford Road, Manchester

PostCode M13 9PL
Email deborah.symmons@manchester.ac.uk
Telephone 01612755044
Fax 01612751640

Full title of study: Prospective observational study of the long term hazards of anti-TNF therapy in rheumatoid arthritis

Lead sponsor: University of Manchester

Name of REC: North West 5 Research Ethics Committee

REC reference number: 00/8/53

Name of lead R&D office: Central Manchester University Hospitals NHS Foundation Trust

Date study commenced: 01/12/2030 (date of original ethical approval)

Protocol reference (if applicable),
current version and date: Main protocol dated 06/10/2003. Two current sub-study protocols: 1) certolizumab and anti-TNF (v3: 15/10/2010) 2) tocilizumab (v1.1: 17/01/2011)

Amendment number and date: Amendment 21: 12/10/2015

Type of amendment

(a) Amendment to information previously given in IRAS

☐ Yes  ☐ No

If yes, please refer to relevant sections of IRAS in the "summary of changes" below.

(b) Amendment to the protocol

☐ Yes  ☐ No

If yes, please submit either the revised protocol with a new version number and date, highlighting changes in bold, or a document listing the changes and giving both the previous and revised text.

(c) Amendment to the information sheet(s) and consent form(s) for participants, or to any other supporting
documentation for the study
  ○ Yes  ○ No
  If yes, please submit all revised documents with new version numbers and dates, highlighting new text in bold.

Is this a modified version of an amendment previously notified and not approved?
  ○ Yes  ○ No
  If yes, please explain the modifications made under "Summary of changes" below

Summary of changes

Briefly summarise the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study.
If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained.

The British Society for Rheumatology has developed a Biologics Registers general information leaflet to be distributed in the rheumatology clinics of sites involved in the BSRBR-RA study. The aim of the leaflet is to make potential participants aware of the study as well as providing a general overview of how it works. This aligns with the NIHR 'OK to Ask' campaign, which is a patient empowerment campaign to emphasise that it is 'OK to ask' about clinical research opportunities that are available. More information can be found about this campaign here:

http://www.cttoolkit.ac.uk/news/itsoktoaskthenihrspatientempowermentcampaign

The leaflet also provides information for researchers on how to access study data and includes links for clinicians regarding which cohorts of drugs are currently open to recruitment.

Any other relevant information

Applicants may indicate any specific issues relating to the amendment, on which the opinion of a reviewing body is sought.

List of enclosed documents

<table>
<thead>
<tr>
<th>Document</th>
<th>Version</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSR - Biologic Registers Leaflet.PDF</td>
<td>v1</td>
<td>23/09/2015</td>
</tr>
</tbody>
</table>

Declaration by Chief Investigator

1. I confirm that the information in this form is accurate to the best of my knowledge and I take full responsibility for it.
2. I consider that it would be reasonable for the proposed amendment to be implemented.

Date of submission: 24/11/15
Signature: [Signature]

Declaration by the sponsor's representative

I confirm the sponsor's support for this substantial amendment.
<table>
<thead>
<tr>
<th>Signature:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Print Name:</td>
</tr>
<tr>
<td>Post:</td>
</tr>
<tr>
<td>Organisation:</td>
</tr>
<tr>
<td>Date:</td>
</tr>
<tr>
<td>(dd/mm/yyyy)</td>
</tr>
</tbody>
</table>
Does this amendment involve new types of exposure or increased exposure to ionising radiation?

☐ Yes    ☐ No

*If Yes, please provide details below:*
Does this amendment involve inclusion of adults lacking capacity or a change to the arrangements relating to adults lacking capacity?

☐ Yes  ☐ No

If Yes, please provide details below:

Declaration by Sponsor’s Representative

This section was signed electronically by Lynne MacRae on 23/11/2015 12:31.

Job Title/Post: Faculty Research Practice Coordinator
Organisation: University of Manchester
Email: lynne.macrae@manchester.ac.uk